A package for a surgical implant includes a body having a side wall including opposite top and bottom ends. The body includes a bottom wall coupled to the bottom end. The body includes a flange extending outwardly from the top end. Inner surfaces of the walls define a cavity. The top end defines an opening that is in communication with the cavity. An insert extends from the bottom wall such that the insert is positioned in the cavity. A lid is configured to be coupled to the flange such that the lid covers the opening. Devices, kits and systems are disclosed.

A surgical system including an implantable medical device having a size and shape. The surgical device having a substrate and a coating that covers at least a portion of the substrate. The coating includes a polymer, collagen, glycerin and a hemostatic agent. The polymer is selected from the group of polyhydroxybutyrate, polyglycerol sebacate and adducts of polyglycerol sebacate. The substrate including a first piece and a second piece that is joined with the first piece. The first piece and the second piece forming a pocket having a cavity and an opening that is in communication with the cavity. The device being pre-formed such that a size and shape of the cavity conforms to the size and shape of the implantable medical device.

A surgical system including an implantable medical device having a size and shape. The surgical device having a substrate and a coating that covers at least a portion of the substrate. The coating including collagen, glycerin and a hemostatic agent. The substrate including a first piece and a second piece that is joined with the first piece. The first piece and the second piece forming a pocket having a cavity and an opening that is in communication with the cavity. The device being pre-formed such that a size and shape of the cavity conforms to the size and shape of the implantable medical device.

The present invention relates to an antibacterial or antifungal composition containing methoxyethyl acrylate.

[Object] To provide a method for producing an absorbent article comprising a fiber assembly layer of a cellulose acetate fiber, which can sufficiently apply a drug to the cellulose acetate fiber.

[Solution] The present invention provides a method for producing an absorbent article, wherein the absorbent article comprises: a fiber assembly layer including a cellulose acetate fiber, and a member including a water absorbent fiber and directly disposed on the fiber assembly layer, the method comprises: a first step of opening a cellulose acetate tow and collecting a cellulose acetate fiber to form a fiber assembly layer; a second step of spreading a drug aqueous solution on the fiber assembly layer; and a third step of mounting the member on the surface where the drug aqueous solution has been spread of the fiber assembly layer, and the drug aqueous solution contains an antibacterial agent and/or a deodorizer, and a surfactant.

[Object] To provide a method for producing an absorbent article comprising a fiber assembly layer of a cellulose acetate fiber, which can sufficiently apply a drug to the cellulose acetate fiber.

[Solution] A method for producing an absorbent article, wherein the absorbent article comprises: a fiber assembly layer including a cellulose acetate fiber, and a member including a water absorbent fiber and directly disposed on the fiber assembly layer, and the method comprises: a first step of opening a cellulose acetate tow and collecting a cellulose acetate fiber to form a fiber assembly layer, a second step of spreading a fiber solvent on the fiber assembly layer and drying the fiber assembly layer; a third step of spreading a drug aqueous solution containing an antibacterial agent and/or a deodorizer on the surface where the fiber solvent has been spread of the fiber assembly layer; and a fourth step of mounting the member on the surface where the drug aqueous solution has been spread of the fiber assembly layer.

Disclosed herein are an ocular lens and a pharmaceutical composition. The ocular lens of the present disclosure is characterized in having a dihydrolipoic acid (DHLA) coated gold nanoclusters absorbed thereon. The pharmaceutical composition of the present disclosure comprises a DHLA coated gold nanocluster, and a pharmaceutically acceptable excipient. According to some embodiments of the present disclosure, the DHLA coated gold nanoclusters are capable of reducing intracellular ROS levels, promoting tissue repair, and inhibiting pathological angiogenesis. Accordingly, also disclosed herein are methods of treating ocular conditions by uses of the present contact lens or pharmaceutical composition.

A nonwoven having a high affinity for an active ingredient is proved, the nonwoven having at least one high surface area fiber in addition to the active ingredient.

A composition for providing or maintaining a healthy skin microbiota and methods of providing or maintaining a healthy skin microbiota are disclosed. The composition can be a prebiotic composition that can include a carrier and a skin microbiota balancing agent. In some aspects, the skin microbiota balancing agent can include at least one combination of carbohydrate sources including a first carbohydrate source and a second carbohydrate source. The skin microbiota balancing agent can be configured to provide at least two of the following desired ratios: a first desired ratio of Corynebaderium to Staphylococcus of 1.3, a second desired ratio of Corynebaderium to Micrococcus of 1.4, and a third desired ratio of Staphylococcus to Micrococcus of 1.1. The carbohydrate sources may be D-alanine, D-threonine, L-alanyl-glycine, succinic acid, α-keto-glutaric acid, m-tantaric acid, bromo succinic acid, mucic acid, phenylethyl-amine, inulin, oxalic acid, pectin, Tween 40 etc.

This disclosure provides generally for antimicrobial compositions and methods of use comprising an anthocyanin, an anthocyanidin or metabolites thereof. Methods for promoting healing of a wound using these compositions are also disclosed. These compositions have broad spectrum antimicrobial activity and are safe for human and animal uses. Further, these compositions are safe for medical uses and industrial uses as antiseptic preparations to reduce or prevent microbial growth, including killing bacterial biofilms.